Apr 27 2026 Teva v. Lilly: The “Well-Known Genus Used as Part of a Different Invention” Doctrine Gets a Federal Circuit Revival By: Brent Nix By: Brent Nix April 27, 2026 Insights On April 16, 2026, the Federal Circuit reversed a District of Massachusetts JMOL that had erased a $176.5 million jury […]... Insights Read More
Oct 27 2025 USPTO Streamlined Claim Set Pilot Program By: Brent Nix By: Brent Nix October 27, 2025 Insights The USPTO launched a new Streamlined Claim Set Pilot Program on October 27, 2025, offering expedited examination for certain utility... Insights Read More
Sep 29 2025 UniCure Reports Positive 3-Year Huntington’s Gene Therapy Data: Unique IP Considerations for Complex Gene Therapy Programs By: Brent Nix By: Brent Nix September 29, 2025 Insights UniCure announced positive 3-year data for their Huntington’s disease gene therapy this week, with the company receiving FDA... Insights Read More
May 16 2025 Willful Enough: How Halozyme Is Putting Merck on Notice By: Erin Daly By: Erin Daly May 16, 2025 General In the ongoing litigation between Halozyme, Inc. and Merck Sharp & Dohme Corp., the issue of willful patent infringement takes... General Read More
Sep 24 2024 Patent Eligibility of Diagnostic Gene Signature Method Claims By: Christopher Southgate By: Christopher Southgate September 24, 2024 Insights A claim drafting strategy assuring the patent subject matter eligibility of diagnostic gene signature method claims is discussed in light... Insights Read More